retatrutide spray Nasal Spray: Triple-Receptor Agonist Research Retatrutide Nasal Spray

All other datasets generated during and/or analyzed during this study are available from the corresponding author on request

Phase II clinical trials showed that participants using retatrutide lost 17.5% of their weight after 24 weeks and 24.2% after 48 weeks

Contact your provider if nosebleeds occur with unusual bruising, bleeding from other sites (gums, gastrointestinal tract), petechiae (small red spots on skin), severe headaches, visual changes, or signs of anemia (fatigue, pallor, shortness of breath)

Deep, constant achingespecially if it travels backward toward your spineis cause for concern

poor storage accelerates degradation